This Article Full Text Full Text (PDF) Supplemental Data Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Meloni, A. Articles by Meager, A. Search for Related Content PubMed PubMed Citation Articles by Meloni, A. Articles by Meager, A. Pubmed/NCBI databases Substance via MeSH Related Collections Adrenal and Hypertension Autoimmunity Calcium and Bone Metabolism

Autoantibodies against Type I Interferons as an Additional Diagnostic Criterion for Autoimmune Polyendocrine Syndrome Type I

Antonella Meloni¹, Maria Furcas, Filomena Cetani¹, Claudio Marcocci, Alberto Falorni¹, Roberto Perniola¹, Mikulá Pura¹, Anette S. Bøe Wolff, Eystein S. Husebye, Desa Lilic¹, Kelli R. Ryan, Andrew R. Gennery, Andrew J. Cant, Mario Abinun, Gavin P. Spickett, Peter D. Arkwright, David Denning, Colm Costigan, Maria Dominguez, Vivienne McConnell, Nick Willcox and Anthony Meager²

Address all correspondence and requests for reprints to: Nick Willcox, Neuroscience Group, Weatherall Institute of Molecular Medicine, University of Oxford, Headington, OX3 9DS Oxford, United Kingdom. E-mail: nick.willcox{at}imm.ox.ac.uk; or Anthony Meager, Biotherapeutics Group, National Institute for Biological Standards and Control, Blanche Lane, South Mimms EN6 3QG, United Kingdom. E-mail: ameager{at}nibsc.ac.uk.

Context: In autoimmune polyendocrinopathy syndrome type I (APS-I), mutations in the autoimmune regulator gene (AIRE) impair thymic self-tolerance induction in developing T cells. The ensuing autoimmunity particularly targets ectodermal and endocrine tissues, but chronic candidiasis usually comes first. We recently reported apparently APS-I-specific high-titer neutralizing autoantibodies against type I interferons in 100% of Finnish and Norwegian patients, mainly with two prevalent AIRE truncations.

Objectives: Because variability in clinical features and age at onset in APS-I frequently results in unusual presentations, we prospectively checked the diagnostic potential of anti-interferon antibodies in additional APS-I panels with other truncations or rare missense mutations and in disease controls with chronic mucocutaneous candidiasis (CMC) but without either common AIRE mutation.

Design: The study was designed to detect autoantibodies against interferon-2 and interferon- in antiviral neutralization assays.

Setting and Patients: Patients included 14 British/Irish, 15 Sardinian, and 10 Southern Italian AIRE-mutant patients with APS-I; also 19 other patients with CMC, including four families with cosegregating thyroid autoimmunity.

Outcome: The diagnostic value of anti-interferon autoantibodies was assessed.

Results: We found antibodies against interferon-2 and/or interferon- in all 39 APS-I patients vs. zero of 48 unaffected relatives and zero of 19 British/Irish CMC patients. Especially against interferon-, titers were nearly always high, regardless of the exact APS-I phenotype/duration or AIRE genotype, including 12 different AIRE length variants or 10 point substitutions overall (n = 174 total). Strikingly, in one family with few typical APS-I features, these antibodies cosegregated over three generations with autoimmune hypothyroidism plus a dominant-negative G228W AIRE substitution.

Conclusions: Otherwise restricted to patients with thymoma and/or myasthenia gravis, these precocious persistent antibodies show 98% or higher sensitivity and APS-I specificity and are thus a simpler diagnostic option than detecting AIRE mutations.